Cognitive Research

Dihexa

4.4/10

BioHarmony verdict

Caution

Dihexa is a gray-market angiotensin IV analog with rodent synaptogenesis and memory data, including McCoy 2013 and Sun 2021, but zero human trials, no human pharmacokinetics, and FDA-noted absence of human exposure data.

Read full report

What is Dihexa?

Dihexa is a synthetic angiotensin IV analog developed as a procognitive research compound. The basic claim is simple: dihexa may help neurons form new synapses by potentiating hepatocyte growth factor signaling at the c-Met receptor, with AT4 / IRAP biology connecting the angiotensin system to memory-related pathways.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Potentiates hepatocyte growth factor signaling at c-Met and is claimed to increase dendritic spine formation and synapse assembly in hippocampal tissue.

Safety watch-outs

  • Severe agitation, mania, or insomnia
  • New neurological symptoms

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Dihexa yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (3)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established
Last checked2026-07-13
Next review2026-10-11

FDA says it has not identified human exposure data for dihexa acetate and lacks enough information to determine whether administration would cause harm.

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.